GHK-Cu: clinical evidence record
Also known as: Copper Tripeptide-1, Glycyl-L-Histidyl-L-Lysine Copper, Prezatide
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-05-22
Independent, and paid nothing. We take no commission, no referral fee and no payment from any retailer, clinic or pharmacy on this site. Outbound links are ordinary untracked links. How we are funded.
AI-friendly summary · GHK-Cu
Discovered by Loren Pickart in 1973. Endogenous in human plasma, declining with age. Extensive cosmetic and wound-healing literature, with limited human RCT-grade efficacy work outside topical formulations. Injectable form is research-tier.
Mechanism of action
How GHK-Cu works
Naturally occurring tripeptide (Glycyl-L-Histidyl-L-Lysine) that complexes copper ions with high affinity. Proposed to modulate gene expression linked to extracellular matrix synthesis, antioxidant signalling, and wound-healing pathways in preclinical and in-vitro models.
Top peer-reviewed citations
Selection of the most-cited peer-reviewed literature on GHK-Cu. Where a verified PMID or DOI is shown, the citation links to the original record. Other citations list the title, authors, journal and year so the reader can locate the paper through the journal index or the PubMed search linked below. PeptideClear publishes editorial commentary, not clinical guidance.
-
GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration
Pickart L, Vasquez-Soltero JM, Margolina A. BioMed research international, 2015.
-
The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health
Pickart L, Vasquez-Soltero JM, Margolina A. Oxidative medicine and cellular longevity, 2012.
-
Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver
Pickart L, Thaler MM. Nature: New biology, 1973.
-
GHK and DNA: resetting the human genome to health
Pickart L, Vasquez-Soltero JM, Margolina A. BioMed research international, 2014.
-
Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+
Maquart FX, Pickart L, Laurent M, et al.. FEBS letters, 1988.
-
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data
Pickart L, Margolina A. International journal of molecular sciences, 2018.
-
Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways
Ma WH, Li M, Ma HF, et al.. Life sciences, 2020.
-
The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice
Park JR, Lee H, Kim SI, et al.. Oncotarget, 2016.
-
Effect of Gly-Gly-His, Gly-His-Lys and their copper complexes on TNF-alpha-dependent IL-6 secretion in normal human dermal fibroblasts
Gruchlik A, Jurzak M, Chodurek E, et al.. Acta poloniae pharmaceutica, 2012.
-
Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes?
Ogórek K, Nowak K, Wadych E, et al.. Molecules (Basel, Switzerland), 2025.
-
Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs
Mazzola J, Rosenfeld M, Tucker M, et al.. Research square, 2026.
-
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Renke G, Chinellato L. International journal of molecular sciences, 2026.
-
The GHK-Cu delays aging in Caenorhabditis elegans via coordinated regulation of mitochondrial function and activation of DAF-16/SKN-1 pathways
Wen H, Zhao K, Luo X, et al.. Biogerontology, 2026.
-
Microenvironment-responsive injectable dynamic hydrogel for sequential antioxidant and tissue regeneration therapy of radiation-induced skin injury
Yu X, Yang T, Bei Z, et al.. Bioactive materials, 2026.
-
The Laccase-like Property of GHK-Cu and Its Applications in Colorimetric Sensing of Phenolic Compounds
Chen JS, Zhu H, Chai TQ, et al.. Biosensors, 2026.
-
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
Mavrych V, Shypilova I, Bolgova O. Frontiers in aging, 2026.
Full PubMed search: https://pubmed.ncbi.nlm.nih.gov/?term=GHK-Cu+copper+tripeptide.
Registered clinical trials
As of 2026-07-13, GHK-Cu has 2 interventional trials listed on ClinicalTrials.gov and the ISRCTN registry. Registration means a study is planned, running or completed. It is not evidence of efficacy, and a listing is not an endorsement.
| Study | Phase | Status | Location | Registry |
|---|---|---|---|---|
| Topical GHK-Cu Gel for Acute Skin Wound Healing NCT07437586 | Phase 2 | Recruiting | China | ClinicalTrials.gov |
| Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types. NCT05932732 | Phase 4 | Completed | United States | ClinicalTrials.gov |
Source: ClinicalTrials.gov and the ISRCTN registry, refreshed 2026-07-13. See the peptide clinical-trials tracker for the full picture across compounds.
UK regulatory status
Plain-English summary of where GHK-Cu sits under the four UK and international frameworks that govern peptide supply. Editorial commentary, not legal advice.
- Misuse of Drugs Act 1971: Not controlled under the Misuse of Drugs Act 1971.
- Psychoactive Substances Act 2016: Not scheduled under the Psychoactive Substances Act 2016.
- MHRA medicines classification: No UK marketing authorisation as a medicine.
- WADA Prohibited List: Not currently listed on the WADA Prohibited List.
Full regulatory record: GHK-Cu UK regulatory status.
Risks and unknowns
What the literature does not yet show about GHK-Cu
Known concerns
- The evidence for GHK-Cu is mixed: some human data exists alongside a larger preclinical literature. Mixed evidence is easy to quote selectively, so check whether a claim you have read rests on the human work or the animal work.
- 2 registered interventional trials exist for GHK-Cu and 1 are recruiting, so the evidence base is actively moving. A registration is not a result, and a recruiting trial has by definition not reported.
- GHK-Cu holds no UK marketing authorisation, so nothing you can buy has been assessed by a regulator, released by batch, or dispensed by an accountable pharmacy. Purity, dose accuracy and sterility rest entirely on the seller's own documentation.
Open questions in the literature
- Long-term outcomes beyond the duration of the published trials are unknown, and the published trials are considerably shorter than the periods over which people actually use these compounds.
- Interactions between GHK-Cu and prescribed medicines are not systematically studied, which matters most for anyone already on treatment for a long-term condition.
- Whether tissue-repair findings in animal injury models translate to the kinds of injury people actually present with, at the timescales they present at, has not been established.
Regulatory note
No UK marketing authorisation as a medicine. Not currently listed on the WADA Prohibited List. The moment a UK seller or commentator makes a therapeutic claim, MHRA can treat the product as an unlicensed medicinal product.
Important: PeptideClear publishes encyclopedia commentary only and does not recommend human use. Speak to a UK-registered prescriber before any medical decision.
Related reading on PeptideClear
Frequently asked questions
What is the evidence level for GHK-Cu?
What is the UK regulatory status of GHK-Cu?
Has GHK-Cu been tested in human clinical trials?
Where can I read the source literature for GHK-Cu?
Last verified 2026-05-22. Editorial commentary, not legal or clinical advice. Citations without a linked identifier can be located through the PubMed search and the journal index.